Upon joining Agilent's Board of Directors on May 1, 2024, McDonnell will become company's President and CEO. In an exclusive interaction with BioSpectrum Asia, both outgoing and incoming CEOs shared their vision for strengthening the life-science potential during their recent visit to the Asia Pacific hub in Singapore.
How is Agilent advancing cell and gene therapy modalities to enable next-gen therapeutics and applications? What are Agilent's strategies for further stabilising its footprint in APAC?
Mike McMullen: Agilent has always been ahead of the curve and aligned with the latest trends in the bioscience industry. The company has achieved a global footprint in life sciences, diagnostics, and applied markets with sales offices, logistics centres, and manufacturing facilities in three major regions. In 2015, Agilent spun off key parts of its operation to become a purely biotechnology company. After acquiring Seahorse Bioscience for $235 million in 2015, Agilent then acquired BioTek Instruments in 2019, & subsequently integrated with Seahorse Bioscience. Together, these three interdisciplinary portfolios give us a very complementary suite of technologies for analysis of cell metabolism & functions. These technologies are likely to be in high demand. Ultimately, Agilent Singapore remains a key operational zone with important investments, especially in the development of new modalities, such as CAR-T cells. Furthermore, in September 2023, Agilent Technologies signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), to develop cell-based therapy advancement. The collaboration aims to boost the nation’s role as a leading cell & gene-therapy manufacturer & clinical services enabling translational research & development.
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia May2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia May2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
